Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries
- PMID: 11790633
Age-related decline in dopamine transporters: analysis of striatal subregions, nonlinear effects, and hemispheric asymmetries
Abstract
Neuroimaging studies have documented an age-related decline in striatal dopamine transporters (DATs) as a marker of dopaminergic neurodegeneration. The authors further elucidated the effects on this neural system in healthy aging, in contrast to Parkinson disease (PD). The effects of age on striatal DAT availability were examined in a large, healthy subject sample (N=126) with [123I]2beta-carbomethoxy-3beta-(4-iodophenyl)tropane ([123I]beta-CIT) and single photon emission computed tomography (SPECT). Striatal DAT availability (V3") showed a significant inverse correlation with age, declining in a nearly linear manner by 46% over the age range 18 to 88 years, or 6.6% per decade. Rates of decline were comparable for caudate (48%) and putamen (45%), with only minimal increase in left-right asymmetry with age. Hemispheric asymmetries were unrelated to the handedness of subjects. These results demonstrate that aging is associated with a relatively symmetric loss of DATs in the caudate and putamen in both hemispheres. These findings have implications not only for healthy aging but also for neurodegenerative disorders such as PD.
Similar articles
-
Imaging serotonin and dopamine transporters with 123I-beta-CIT SPECT: binding kinetics and effects of normal aging.J Nucl Med. 2000 Jan;41(1):36-44. J Nucl Med. 2000. PMID: 10647603
-
Iodine-123-N-omega-fluoropropyl-2beta-carbomethoxy-3beta-(4-iod ophenyl)tropane SPECT in healthy controls and early-stage, drug-naive Parkinson's disease.J Nucl Med. 1998 Jul;39(7):1143-8. J Nucl Med. 1998. PMID: 9669384
-
Age-related decline in striatal dopamine transporter binding with iodine-123-beta-CITSPECT.J Nucl Med. 1995 Jul;36(7):1175-81. J Nucl Med. 1995. PMID: 7790941
-
Test/retest reproducibility of iodine-123-betaCIT SPECT brain measurement of dopamine transporters in Parkinson's patients.J Nucl Med. 1997 Sep;38(9):1453-9. J Nucl Med. 1997. PMID: 9293807
-
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression.JAMA. 2002 Apr 3;287(13):1653-61. doi: 10.1001/jama.287.13.1653. JAMA. 2002. PMID: 11926889 Clinical Trial.
Cited by
-
Anger, agency, risk and action: a neurobehavioral model with proof-of-concept in healthy young adults.Front Psychol. 2023 May 30;14:1060877. doi: 10.3389/fpsyg.2023.1060877. eCollection 2023. Front Psychol. 2023. PMID: 37325735 Free PMC article.
-
A scoping review of neurodegenerative manifestations in explainable digital phenotyping.NPJ Parkinsons Dis. 2023 Mar 30;9(1):49. doi: 10.1038/s41531-023-00494-0. NPJ Parkinsons Dis. 2023. PMID: 36997573 Free PMC article. Review.
-
Neuroprotection in late life attention-deficit/hyperactivity disorder: A review of pharmacotherapy and phenotype across the lifespan.Front Hum Neurosci. 2022 Sep 26;16:938501. doi: 10.3389/fnhum.2022.938501. eCollection 2022. Front Hum Neurosci. 2022. PMID: 36226261 Free PMC article. Review.
-
Peri-lead edema and local field potential correlation in post-surgery subthalamic nucleus deep brain stimulation patients.Front Hum Neurosci. 2022 Sep 8;16:950434. doi: 10.3389/fnhum.2022.950434. eCollection 2022. Front Hum Neurosci. 2022. PMID: 36158622 Free PMC article.
-
Serial changes of I-123 FP-CIT SPECT binding asymmetry in Parkinson's disease: Analysis of the PPMI data.Front Neurol. 2022 Sep 1;13:976101. doi: 10.3389/fneur.2022.976101. eCollection 2022. Front Neurol. 2022. PMID: 36119683 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical